1.00Open1.15Pre Close18 Volume60 Open Interest20.00Strike Price1.84KTurnover41.00%IV6.11%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry1.10Extrinsic Value100Contract SizeAmericanOptions Type-0.4455Delta0.2322Gamma33.55Leverage Ratio-0.0210Theta-0.0037Rho-14.95Eff Leverage0.0164Vega
IDEAYA Biosciences Stock Discussion
Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial
Breakthrough: First-in-Class Cancer Drug Combination Shows Promise in Bladder Cancer Study
Breakthrough Cancer Treatment: IDEAYA's IDE275 Targets Major Tumor Types with GSK Backing
Major Clinical Trial Update: IDEAYA's Novel Cancer Drug Targets 48,000 Annual NSCLC Cases
IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen
The agreement grants IDEAYA an option for an exclusive worldwide license from Biocytogen for a potential first-in-class B7H3/PTK7 topo-I-payload BsADC program. B7H3/PTK7 has been found to be co-expressed in multiple solid tumor types, including double-digit percent prevalence in...
📊⚡️📊
No comment yet